CD40.Pan.CoV Vaccine(CD40.Pan.CoV Vaccine) - 在研适应症：新型冠状病毒感染_专利_临床

概要

基本信息

药物类型

预防性疫苗

别名-

靶点-

作用方式

刺激剂

作用机制

免疫刺激剂

治疗领域

感染呼吸系统疾病

在研适应症

新型冠状病毒感染

非在研适应症-

原研机构

ANRS Emerging infectious diseases

在研机构

ANRS Emerging infectious diseases

非在研机构-

权益机构-

最高研发阶段临床1/2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

关联

1

项与 CD40.Pan.CoV Vaccine 相关的临床试验

NCT07113106

/ Recruiting临床1/2期IIT

A Phase 1/2a Multicenter Trial to Evaluate the Safety and Immunogenicity of the CD40.Pan.CoV Vaccine, Adjuvanted or Not, as a Booster in Adult Participants

The clinical trial is a phase1/2a, open-label, dose-escalating, multicentre trial evaluating the safety and immunogenicity of the CD40.Pan.CoV vaccine, adjuvanted or not, as a booster injection in adult participants in France. 48 participants divided into 4 cohorts will be included in the trial.
Primary objectives are the following:
* To determine the safety and reactogenicity of different doses (0.25 mg and 1 mg) of a booster of a CD40.Pan.CoV vaccine, adjuvanted or not, in healthy volunteers between Day 0 and Month1
* To determine the humoral immune response (neutralizing antibody titers) induced by different doses (0.25 mg and 1 mg) of a booster of a CD40.Pan.CoV vaccine, adjuvanted or not, at Month1 after administration

开始日期2025-06-18

申办/合作机构

ANRS Emerging infectious diseases

[+1]

100 项与 CD40.Pan.CoV Vaccine 相关的临床结果

登录后查看更多信息

100 项与 CD40.Pan.CoV Vaccine 相关的转化医学

登录后查看更多信息

100 项与 CD40.Pan.CoV Vaccine 相关的专利（医药）

登录后查看更多信息

100 项与 CD40.Pan.CoV Vaccine 相关的药物交易

登录后查看更多信息